Experience

Variant Bio

• United States
• Biotechnology Research
• 1 - 100 Employee

• Scientist

  • Jan 2023 - Present

  Seattle, Washington, United States

• Senior Associate Scientist

  • Jan 2022 - Jan 2023

  Seattle, Washington, United States



University of Washington

• United States
• Higher Education
• 700 & Above Employee

• Research Scientist III and Laboratory Manager, Department of Neurology

  • Jun 2015 - Jan 2022

  Seattle, WA Participated in developing experimental plans and research activities to characterize molecular and cellular mechanisms of peripheral and central nervous system involved in initiating, promoting, or protecting against neurodegeneration and Alzheimer’s disease. ✔ Characterized molecular and cellular effects of mutations associated with Alzheimer’s disease in patient specimens of various cell types, including induced pluripotent stem cells (iPSCs) ✔ Responsible for maintaining all basic… Show more Participated in developing experimental plans and research activities to characterize molecular and cellular mechanisms of peripheral and central nervous system involved in initiating, promoting, or protecting against neurodegeneration and Alzheimer’s disease. ✔ Characterized molecular and cellular effects of mutations associated with Alzheimer’s disease in patient specimens of various cell types, including induced pluripotent stem cells (iPSCs) ✔ Responsible for maintaining all basic laboratory functions, protocols, equipment, compliance, and SOPs in compliance with UW policies and procedures ✔Supervise and/or mentor Research Scientists, Student Assistants, and Undergraduate Researchers Show less



RTI International

• United States
• Research Services
• 700 & Above Employee

• Intern, Global Noncommunicable Disease Initiative (MPH Practicum)

  • Jan 2019 - May 2019

  Seattle, WA In final year of MPH studies, worked to identify metrics that could be used to assess value-based care for noncommunicable disease service delivery in low-middle income countries in the context of universal health coverage. Gathered epidemiological and health policy evidence for the use of patient-reported outcome measures. Summarized findings to project personnel, wrote content for publication, and contributed to content presented to both internal and external stakeholders.



Amgen

• United States
• Biotechnology Research
• 700 & Above Employee

• Scientist, Department of Inflammation

  • 2010 - 2014

  Seattle, WA Project Leader for an Inflammatory Bowel Disease (IBD) discovery stage target within Inflammation Research. Authored internal research reports and peer-reviewed manuscripts. Originally hired at Immunex, then transitioned to Amgen during acquisition in 2002. ✔ Project leader for an IBD discovery stage target: developed prioritized, and executed the overall project strategy, research collaborations and experimental plan to meet all project goals and timelines. ✔ Presented project… Show more Project Leader for an Inflammatory Bowel Disease (IBD) discovery stage target within Inflammation Research. Authored internal research reports and peer-reviewed manuscripts. Originally hired at Immunex, then transitioned to Amgen during acquisition in 2002. ✔ Project leader for an IBD discovery stage target: developed prioritized, and executed the overall project strategy, research collaborations and experimental plan to meet all project goals and timelines. ✔ Presented project updates and project proposals to intradepartmental staff, including executives. ✔ As in vivo project team representative for a novel TNF family member target, coordinated internal in vivo activities and schedules, sourced/evaluated in vivo models from CRO partners, and supported out-licensing due diligence efforts. ✔ Authored and served as Principle Investigator for internal IACUC animal-use protocols.

• Senior Associate Scientist, Department of Inflammation

  • 2005 - 2010

  Seattle, WA Independently designed and led experiments to characterize efficacy of novel therapeutic candidates in acute and chronic inflammatory disease. Validated novel targets for the development of innovative therapeutics for inflammatory and autoimmune diseases. ✔ Characterized the in vivo effects of an IL-22 agonist in non-disease mice. Profiled alterations in serum biomarkers, gene expression, receptor signaling, complete blood count, clinical chemistry, and epithelial cell… Show more Independently designed and led experiments to characterize efficacy of novel therapeutic candidates in acute and chronic inflammatory disease. Validated novel targets for the development of innovative therapeutics for inflammatory and autoimmune diseases. ✔ Characterized the in vivo effects of an IL-22 agonist in non-disease mice. Profiled alterations in serum biomarkers, gene expression, receptor signaling, complete blood count, clinical chemistry, and epithelial cell proliferation. ✔ Developed and optimized in vitro assays to evaluate the effects of an IL-22 agonist on a broad range of immune responses including cell signaling, proliferation, cytokine/chemokine secretion, and phagocytosis using human and mouse cell lines and mouse macrophages. ✔ Identified serum biomarkers (mouse, human, non-human primate) for novel therapeutic candidates.

• Associate Scientist, Department of Inflammation

  • 2001 - 2005

  Seattle, WA Developed, optimized, and performed proliferation, mixed lymphocyte reaction (MLR), immunoglobulin secretion, and neutralization assays to evaluate the biological effects of a TNF family member antagonist in human and mouse primary T and B cells and cell lines. ✔ Screened candidate antibodies for binding to human cells (flow cytometry) and cytokine inhibition in whole blood assays. ✔ Confirmed activity and determined IC50 values of surrogate antibodies for use in preclinical… Show more Developed, optimized, and performed proliferation, mixed lymphocyte reaction (MLR), immunoglobulin secretion, and neutralization assays to evaluate the biological effects of a TNF family member antagonist in human and mouse primary T and B cells and cell lines. ✔ Screened candidate antibodies for binding to human cells (flow cytometry) and cytokine inhibition in whole blood assays. ✔ Confirmed activity and determined IC50 values of surrogate antibodies for use in preclinical models. ✔ Worked independently to design and conduct experiments to characterize the efficacy of novel therapeutic candidates in acute and chronic mouse models of inflammatory disease.



Corixa Corporation

• United States
• Biotechnology
• 1 - 100 Employee

• Senior Research Associate, Department of Immunology

  • 1997 - 2001

  Seattle, WA Supported novel cancer antigen discovery for generation of tumor vaccines through in vitro and in vivo assay development. Worked to identify novel tumor antigens using T cell expression cloning and development of tumor-specific T cells. Managed and conducted experiments in a population of SCID mice with human tumor xenografts. ✔ Generated and characterized tumor specific T cells (CD4+/CD8+) and evaluated expansion and screening methods. ✔ Established in vitro tumor cell lines from… Show more Supported novel cancer antigen discovery for generation of tumor vaccines through in vitro and in vivo assay development. Worked to identify novel tumor antigens using T cell expression cloning and development of tumor-specific T cells. Managed and conducted experiments in a population of SCID mice with human tumor xenografts. ✔ Generated and characterized tumor specific T cells (CD4+/CD8+) and evaluated expansion and screening methods. ✔ Established in vitro tumor cell lines from patient specimens of various tumor types. ✔ Optimized protocols for retroviral transduction and adenoviral infection of tumor cell lines. Show less



Targeted Genetics

• Biotechnology Research
• 1 - 100 Employee

• Research Assistant II, Department of Immunology

  • 1993 - 1997

  Seattle, WA Researched adoptive immunotherapy of genetically modified T cells as part of murine tumor studies and vaccine development. Optimized efficiency of retroviral gene transfer into human T cells and developed assays for quantifying transduction efficiency for several reporter systems.



Invitrogen

• Biotechnology Research
• 1 - 100 Employee

• Senior Production Assistant, Department of Biologics Production

  • 1991 - 1993

  San Diego, CA Produced, quality-tested, and purified biologic components for molecular cloning applications in a laboratory environment. Worked independently in oligonucleotide production/analysis and FPLC purification, including ion exchange and gel filtration chromatography.